San Diego, CA, United States of America

John M Keith

USPTO Granted Patents = 28 

 

 

Average Co-Inventor Count = 5.4

ph-index = 5

Forward Citations = 85(Granted Patents)


Company Filing History:


Years Active: 2008-2025

Loading Chart...
Loading Chart...
Loading Chart...
28 patents (USPTO):

Title: Innovations by John M. Keith in IL-17 Modulation

Introduction

John M. Keith, based in San Diego, CA, is a prolific inventor with a remarkable portfolio of 27 patents. His work primarily focuses on pharmaceutical innovations, particularly in the modulation of immune responses. Keith's contributions have significantly advanced therapeutic approaches in addressing various diseases linked to the IL-17 pathway.

Latest Patents

Among his latest patents, John M. Keith has developed compounds classified as imidazopyridazines, which act as modulators of IL-17. The present application discloses specific compounds, including their pharmaceutically acceptable salts. The formulations outlined in his patents provide methods for treating or ameliorating IL-17 mediated syndromes, disorders, and diseases, showcasing his commitment to enhancing treatment modalities in immunology.

Career Highlights

Throughout his career, Keith has aligned himself with notable pharmaceutical companies, including Janssen Pharmaceutica NV and Janssen Pharmaceutica BV. His roles in these organizations have allowed him to innovate and develop groundbreaking therapeutic agents that leverage his expertise in medicinal chemistry and pharmacology.

Collaborations

John M. Keith's work has involved collaborations with several esteemed professionals, including Natalie Anne Hawryluk and William Moore Jones. These partnerships have fostered a collaborative environment that has been crucial for the success of his innovations in the pharmaceutical field.

Conclusion

John M. Keith stands out as a key figure in the realm of pharmaceutical innovation. His extensive portfolio of patents and collaborations underscores his dedication to advancing medical science and improving patient care through targeted therapeutic strategies in the modulation of IL-17. His ongoing contributions continue to shape the landscape of modern medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…